Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Lipid Disorders and Pregnancy.
Endocrinol Metab Clin North Am
September 2024
Department of Medicine, New York University Grossman School of Medicine, New York, USA; Holman Division of Endocrinology, Diabetes & Metabolism, New York University Grossman School of Medicine, New York, USA. Electronic address:
Practicing endocrinologists are likely to confront 2 major issues that occur with dyslipidemias during pregnancy. The most dramatic is the development of severe hypertriglyceridemia leading to acute pancreatitis. The second is the approach to treatment of familial hypercholesterolemia, a common genetic disorder.
View Article and Find Full Text PDFWomen and lipoprotein apheresis: another side of gender medicine.
Endocrine
December 2024
Lipoapheresis Unit - Reference Center for Diagnosis and Treatment of Inherited Dyslipidemias, Fondazione Toscana "Gabriele Monasterio", Via Moruzzi 1, Pisa, 56124, Italy.
Aim: In heterozygous Familial Hypercholesterolemia (FH) woman atherosclerotic cardiovascular disease occurs 20-years earlier respect woman without FH while homozygous FH women may suffer from atherosclerotic cardiovascular disease even in childhood. Lipoprotein apheresis, a therapeutic "last chance saloon", is a well-tolerated procedure that markedly lowers LDL-cholesterol and Lp(a) levels in patients who do not achieve acceptable levels with maximal lifestyle and drug therapy.
Methods And Results: The experience of LA treatment in 3 female homozygous FH patients was described.
International Atherosclerosis Society Roadmap for Familial Hypercholesterolaemia.
Glob Heart
January 2024
Lipid Clinic, Heart Institute (InCor), University of São Paulo, São Paulo, Brazil and Hospital Israelita Albert Einstein, São Paulo, Brazil.
Familial hypercholesterolaemia (FH), a common monogenic disorder, is a preventable cause of premature coronary artery disease and death. Up to 35 million people worldwide have FH, but most remain undetected and undertreated. Several clinical guidelines have addressed the gaps in care of FH, but little focus has been given to implementation science and practice.
View Article and Find Full Text PDFPCSK9 inhibitor use during pregnancy in a case of familial hypercholesterolemia complicated with coronary artery disease.
J Obstet Gynaecol Res
January 2024
Tokyo Medical and Dental University, Perinatal and Women's Medicine, Tokyo, Japan.
Limited data have been reported on the use of proprotein convertase subtilisin/kexin type 9 (PCSK 9) inhibitors during pregnancy in women with familial hypercholesterolemia (FH). Here, we present the first case of initiating evolocumab (PCSK9 inhibitor) in a compound heterozygous FH mother. The patient was a 34-year-old primipara with severe dyslipidemia and a history of coronary artery bypass surgery.
View Article and Find Full Text PDFSex Differences in Familial Hypercholesterolemia.
Curr Atheroscler Rep
November 2023
Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.
Purpose Of Review: This review aims to summarize the existing research on sex differences in familial hypercholesterolemia (FH) across the lifespan.
Recent Findings: From childhood onward, total- and low-density lipoprotein cholesterol (LDL-C) levels in girls are higher than those in boys with FH. By the age of 30 years, women with FH have a higher LDL-C burden than men.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!